Organization | Jyväskylä Central Hospital

Jyväskylä Central Hospital Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial

2017

NCT03236961

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Jyväskylä Central Hospital

Active Ingredients

Drugs in Phase 1 Trials (1)

egfrviii-specific hinge-optimized cd3 ζ-stimulatory/41bb-co-stimulatory chimeric antigen receptor autologous t-lymphocytes (1 trial)

Drugs in Other Trials (4)

ertapenem (invanz) (2 trials)

levofloxacin (levaquin) (1 trial)

metronidazole (flagyl) (1 trial)

moxifloxacin (avelox) (2 trials)

Indications

Overview

Highest Phase: Phase 1
# of Trials: 3
# of Trial APIs: 5